Carisma Therapeutics (NASDAQ:CARM) Given New $1.00 Price Target at D. Boral Capital
Carisma Therapeutics (NASDAQ:CARM – Get Free Report) had its price objective cut by equities researchers at D. Boral Capital from $12.00 to $1.00 in a report issued on Tuesday,Benzinga reports. The ...
HC Wainwright Issues Pessimistic Forecast for BioNTech (NASDAQ:BNTX) Stock Price
BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...
Inventiva achieves milestone with Phase 3 study enrollment, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce affirms a Buy rating on shares of Inventiva (IVA) after the company announced the completion of patient ...